Please note that this website has a UK government access keys system.
Advisory bodies assist in evaluating, investigating and supporting policy development in key areas.
The Group developed proposals on the statutory regulation of the acupuncture profession, which were put forward for consultation in 2003.
The Committee regulates the administration of radioactive medicinal products by doctors and dentists to patients.
The Committee was established in April 2007 to provide practical and scientific advice to the Government on strategies to minimise the incidence of healthcare associated infections and to maintain the effectiveness of antimicrobial agents in the treatment and prevention of microbial infections in man and animals.
The Committee oversees awards that recognise and reward the exceptional contribution of NHS consultants
The Committee advises on all aspects of hazards and risks from exposure to pathogens.
The Committee advises on the microbiological safety of blood and tissues for transplantation.
The Committee advises on the most appropriate ways to ensure the safety of blood, cells, tissues and organs for transfusion / transplantation.
The Committee advises on the prevention and control of viral hepatitis in the community and in health care settings.
The Group advises on the modernisation and reform of current NHS pharmacy regulations.
The Committee advises on the carcinogenicity of chemicals.
The Committee assesses and advises on the health effects of natural and man-made radiation in the environment.
The Committee advises on the potential mutagenicity of chemicals.
The Committee advises on the toxicity and effects upon health of air pollutants.
The Committee advises on the toxicity of chemicals.
The Group oversees the implementation of the recommendations in the Report of the Expert Group on the Regulation of Cosmetic Surgery.
The Group advises on AIDS-related matters.
The Committee evaluates genetic tests and their relevance to insurance.
The Committee advises on developments in gene therapy research and their implications.
The Task Force develops and stimulates the growth and performance of the UK healthcare industry to maximise the benefit to patients.
The Working Group developed recommendations for the regulation of the herbal medicine profession, which were put forward for consultation in 2003.
The Commission advises the Government on the social, ethical and legal issues around human genetics.
The aim of the Immunisation Group Web Programme is to work, in partnership with NHS and arms length body colleagues and stakeholders, to improve the track and traceability of vaccine products and immunisation processes and provide a shared communications platform for exchanging appropriate information.
The Committee advises on communicable diseases, preventable and potentially preventable through immunisation.
The Working Group advises on the modernisation of maternity services.
Handles certificate requests from doctors and dentists wishing to administer radioactive medicinal products to humans.
The National Clinical Audit Advisory Group (NCAAG) has been established to drive the reinvigoration programme and provide a national focus for discussion and advice on matters relating to clinical audit. The NCAAG will also be the steering group for the expanded National Clinical Audit and Patients' Outcomes Programme (NCAPOP).
This is an over-arching horizon-scanning panel, reporting to the Chief Medical Officer and advising the Department of Health on the threat from new and emerging infectious diseases.
The Group aims to improve access to uncommon services and to sustain high levels of expertise by preventing proliferation of too many centres.
The Forum works to improve health through changes in dietary habits.
The Group advises on the implementation of the recommendations of the Kennedy Report for paediatric and congenital cardiac services following the tragic failures at Bristol Royal Infirmary.
The Group ensures that patients' rights are maintained when the NHS and other health-related organisations use medical information about them.
The Task Force aims to strengthen the competitiveness of the UK business environment for the innovative pharmaceutical industry.
Committee advises on the nutrient content of individual foods, diet and the nutritional status of people.
The Committee advises on the health effects of smoking.
Providing specialist scientific advice to the UK Health Departments on the health response during an influenza pandemic.
The Commission works with Ministers to oversee the revision of the Prime Minister's strategy on carers.
The Committee advises on dental matters.
The Committee advised on the provisions of medical, nursing and midwifery, dental, and pharmaceutical services. It was abolished in May 2005.
The Committee advised on strategic issues for the nursing and midwifery professions. It was abolished in May 2005.
Providing specialist advice to the UK Health Departments on the health response during an influenza pandemic.
UKXIRA ceased to exist from 12 December 2006. This change follows a number of amendments to the statutory framework. Other Government Committees, Research Ethics Committees, and clinical governance arrangements are absorbing the functions.
The Group advises on the surveys for HIV and other infectious diseases.
With effect from 1st September 2006, the functions carried out by the Unrelated Live Transplant Regulatory Authority (ULTRA) transferred to the Human Tissue Authority (HTA). This change followed the full implementation of the Human Tissue Act 2004 and the Human Tissue (Scotland) Act 2006.
